Last reviewed · How we verify
PrEP with Truvada®
At a glance
| Generic name | PrEP with Truvada® |
|---|---|
| Also known as | Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
- IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya (EARLY_PHASE1)
- Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PHASE3)
- Integrated HIV Prevention and HCV Care for PWID (NA)
- STI Testing to Enhance PrEP Use in Pregnancy (PHASE3)
- A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP (PHASE2)
- Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV (NA)
- Prevention of HIV in "Île-de-France" (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PrEP with Truvada® CI brief — competitive landscape report
- PrEP with Truvada® updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI